ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2025
Predictive value of a mesenchymal phenotype grading system combining tumor budding and FRMD6 expression for disease-free survival in colorectal carcinomas.
Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesThe mesenchymal phenotype in solid epithelial tumors contributes to aggressive outcomes. This study examined histological indicators of tumor mesenchymal phenotypes, including the Glasgow Microenvironment Score (GMS), tumor budding (TB) grades and Ferm Containing Domain 6 (FRMD6) expression in colorectal carcinomas (CRC) and correlated these with disease-free survival (DFS).
methodsTotal 101 CRC cases were included. Peri-tumoral inflammation was classified as low (none/mild) and high (band/dense cup-like) infiltration. Tumor stromal percentage was assessed as low (≤ 50% intra-tumor stroma) and high (> 50% fibrosis) based on intra-tumoral fibrosis. TB at the invasive border was categorized as low (0-9/0.785 mm
resultsThe mean DFS in this cohort was 19.7 months. While the GMS grades did not correlate with DFS at 36 months (p 0.71) and 48 months (p 0.79), TB and FRMD6 grades separately were significantly correlated with DFS at 36 months (TB p 0.001 and FRMD6 p 0.004) and 48 months (TB p 0.002 and FRMD6 p 0.008). When combined, the mesenchymal classification using GMS + TB + FRMD6 did not show correlation with DFS at 36 months (p 0.09) and 48 months (p 0.49). However, mesenchymal phenotyping combining TB + FRMD6 showed a significant correlation with DFS both at 36 months (p < 0.001) and 48 months (p < 0.001) in multivariate analysis. In this cohort, CRCs with low-GMS, low-TB and low-TB + GMS grades were found to be mostly mismatch repair (MMR) deficient (GMS p 0.007, TB p 0.03 and GMS + TB p 0.009).
conclusionMesenchymal tumor phenotyping combining TB and FRMD6 expression correlates well with DFS in CRCs.
Indexed as
Identifiers
40974447What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.